🇺🇸 FDA
Pipeline program

GLPG3970

GLPG3970-CL-209

Phase 2 small_molecule completed

Quick answer

GLPG3970 for Rheumatoid Arthritis is a Phase 2 program (small_molecule) at Lakefront Biotherapeutics NV with 1 ClinicalTrials.gov record(s).

Program details

Company
Lakefront Biotherapeutics NV
Indication
Rheumatoid Arthritis
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials